Copyright Reports & Markets. All rights reserved.

Global Acute Myeloid Leukaemia Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Acute Myeloid Leukaemia Therapeutics
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Acute Myeloid Leukaemia Therapeutics by Type
    • 1.3.1 Overview: Global Acute Myeloid Leukaemia Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Type in 2022
    • 1.3.3 Chemotherapy
    • 1.3.4 Targeted Therapy
    • 1.3.5 Immunotherapy
    • 1.3.6 Hypomethylating Agents
    • 1.3.7 Others
  • 1.4 Global Acute Myeloid Leukaemia Therapeutics Market by Application
    • 1.4.1 Overview: Global Acute Myeloid Leukaemia Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Specialty Clinics
    • 1.4.3 Hospital
    • 1.4.4 Others
  • 1.5 Global Acute Myeloid Leukaemia Therapeutics Market Size & Forecast
  • 1.6 Global Acute Myeloid Leukaemia Therapeutics Market Size and Forecast by Region
    • 1.6.1 Global Acute Myeloid Leukaemia Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Acute Myeloid Leukaemia Therapeutics Market Size by Region, (2018-2029)
    • 1.6.3 North America Acute Myeloid Leukaemia Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Acute Myeloid Leukaemia Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.6 South America Acute Myeloid Leukaemia Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Acute Myeloid Leukaemia Therapeutics Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Pfizer Inc.
    • 2.1.1 Pfizer Inc. Details
    • 2.1.2 Pfizer Inc. Major Business
    • 2.1.3 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.1.4 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Pfizer Inc. Recent Developments and Future Plans
  • 2.2 Novartis AG
    • 2.2.1 Novartis AG Details
    • 2.2.2 Novartis AG Major Business
    • 2.2.3 Novartis AG Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.2.4 Novartis AG Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Novartis AG Recent Developments and Future Plans
  • 2.3 Celgene Corporation
    • 2.3.1 Celgene Corporation Details
    • 2.3.2 Celgene Corporation Major Business
    • 2.3.3 Celgene Corporation Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.3.4 Celgene Corporation Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Celgene Corporation Recent Developments and Future Plans
  • 2.4 Astellas Pharma Inc.
    • 2.4.1 Astellas Pharma Inc. Details
    • 2.4.2 Astellas Pharma Inc. Major Business
    • 2.4.3 Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.4.4 Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Astellas Pharma Inc. Recent Developments and Future Plans
  • 2.5 Daiichi Sankyo Company, Limited
    • 2.5.1 Daiichi Sankyo Company, Limited Details
    • 2.5.2 Daiichi Sankyo Company, Limited Major Business
    • 2.5.3 Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.5.4 Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Daiichi Sankyo Company, Limited Recent Developments and Future Plans
  • 2.6 Jazz Pharmaceuticals
    • 2.6.1 Jazz Pharmaceuticals Details
    • 2.6.2 Jazz Pharmaceuticals Major Business
    • 2.6.3 Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.6.4 Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Jazz Pharmaceuticals Recent Developments and Future Plans
  • 2.7 Boehringer Ingelheim International GmbH
    • 2.7.1 Boehringer Ingelheim International GmbH Details
    • 2.7.2 Boehringer Ingelheim International GmbH Major Business
    • 2.7.3 Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.7.4 Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Boehringer Ingelheim International GmbH Recent Developments and Future Plans
  • 2.8 Johnson & Johnson
    • 2.8.1 Johnson & Johnson Details
    • 2.8.2 Johnson & Johnson Major Business
    • 2.8.3 Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.8.4 Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Johnson & Johnson Recent Developments and Future Plans
  • 2.9 Gilead Sciences, Inc.
    • 2.9.1 Gilead Sciences, Inc. Details
    • 2.9.2 Gilead Sciences, Inc. Major Business
    • 2.9.3 Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.9.4 Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Gilead Sciences, Inc. Recent Developments and Future Plans
  • 2.10 Amgen Inc.
    • 2.10.1 Amgen Inc. Details
    • 2.10.2 Amgen Inc. Major Business
    • 2.10.3 Amgen Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.10.4 Amgen Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Amgen Inc. Recent Developments and Future Plans
  • 2.11 Takeda Pharmaceutical Company Limited
    • 2.11.1 Takeda Pharmaceutical Company Limited Details
    • 2.11.2 Takeda Pharmaceutical Company Limited Major Business
    • 2.11.3 Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.11.4 Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
  • 2.12 Sunesis Pharmaceuticals, Inc.
    • 2.12.1 Sunesis Pharmaceuticals, Inc. Details
    • 2.12.2 Sunesis Pharmaceuticals, Inc. Major Business
    • 2.12.3 Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.12.4 Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 Sunesis Pharmaceuticals, Inc. Recent Developments and Future Plans
  • 2.13 Agios Pharmaceuticals, Inc.
    • 2.13.1 Agios Pharmaceuticals, Inc. Details
    • 2.13.2 Agios Pharmaceuticals, Inc. Major Business
    • 2.13.3 Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.13.4 Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 Agios Pharmaceuticals, Inc. Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Acute Myeloid Leukaemia Therapeutics Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Acute Myeloid Leukaemia Therapeutics by Company Revenue
    • 3.2.2 Top 3 Acute Myeloid Leukaemia Therapeutics Players Market Share in 2022
    • 3.2.3 Top 6 Acute Myeloid Leukaemia Therapeutics Players Market Share in 2022
  • 3.3 Acute Myeloid Leukaemia Therapeutics Market: Overall Company Footprint Analysis
    • 3.3.1 Acute Myeloid Leukaemia Therapeutics Market: Region Footprint
    • 3.3.2 Acute Myeloid Leukaemia Therapeutics Market: Company Product Type Footprint
    • 3.3.3 Acute Myeloid Leukaemia Therapeutics Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Acute Myeloid Leukaemia Therapeutics Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global Acute Myeloid Leukaemia Therapeutics Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Acute Myeloid Leukaemia Therapeutics Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2018-2029)
  • 6.2 North America Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2018-2029)
  • 6.3 North America Acute Myeloid Leukaemia Therapeutics Market Size by Country
    • 6.3.1 North America Acute Myeloid Leukaemia Therapeutics Consumption Value by Country (2018-2029)
    • 6.3.2 United States Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2018-2029)
  • 7.2 Europe Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2018-2029)
  • 7.3 Europe Acute Myeloid Leukaemia Therapeutics Market Size by Country
    • 7.3.1 Europe Acute Myeloid Leukaemia Therapeutics Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.3 France Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size by Region
    • 8.3.1 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Consumption Value by Region (2018-2029)
    • 8.3.2 China Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.5 India Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2018-2029)
  • 9.2 South America Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2018-2029)
  • 9.3 South America Acute Myeloid Leukaemia Therapeutics Market Size by Country
    • 9.3.1 South America Acute Myeloid Leukaemia Therapeutics Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Size by Country
    • 10.3.1 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Acute Myeloid Leukaemia Therapeutics Market Drivers
  • 11.2 Acute Myeloid Leukaemia Therapeutics Market Restraints
  • 11.3 Acute Myeloid Leukaemia Therapeutics Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Acute Myeloid Leukaemia Therapeutics Industry Chain
  • 12.2 Acute Myeloid Leukaemia Therapeutics Upstream Analysis
  • 12.3 Acute Myeloid Leukaemia Therapeutics Midstream Analysis
  • 12.4 Acute Myeloid Leukaemia Therapeutics Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Acute Myeloid Leukaemia Therapeutics market size was valued at USD 3601.3 million in 2022 and is forecast to a readjusted size of USD 7125.8 million by 2029 with a CAGR of 10.2% during review period.
    The Global Info Research report includes an overview of the development of the Acute Myeloid Leukaemia Therapeutics industry chain, the market status of Specialty Clinics (Chemotherapy, Targeted Therapy), Hospital (Chemotherapy, Targeted Therapy), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Acute Myeloid Leukaemia Therapeutics.
    Regionally, the report analyzes the Acute Myeloid Leukaemia Therapeutics markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Acute Myeloid Leukaemia Therapeutics market, with robust domestic demand, supportive policies, and a strong manufacturing base.
    Key Features:
    The report presents comprehensive understanding of the Acute Myeloid Leukaemia Therapeutics market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Acute Myeloid Leukaemia Therapeutics industry.
    The report involves analyzing the market at a macro level:
    Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Chemotherapy, Targeted Therapy).
    Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Acute Myeloid Leukaemia Therapeutics market.
    Regional Analysis: The report involves examining the Acute Myeloid Leukaemia Therapeutics market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
    Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Acute Myeloid Leukaemia Therapeutics market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
    The report also involves a more granular approach to Acute Myeloid Leukaemia Therapeutics:
    Company Analysis: Report covers individual Acute Myeloid Leukaemia Therapeutics players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
    Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Acute Myeloid Leukaemia Therapeutics This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Specialty Clinics, Hospital).
    Technology Analysis: Report covers specific technologies relevant to Acute Myeloid Leukaemia Therapeutics. It assesses the current state, advancements, and potential future developments in Acute Myeloid Leukaemia Therapeutics areas.
    Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Acute Myeloid Leukaemia Therapeutics market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
    Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
    Market Segmentation
    Acute Myeloid Leukaemia Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
    Market segment by Type
    Chemotherapy
    Targeted Therapy
    Immunotherapy
    Hypomethylating Agents
    Others
    Market segment by Application
    Specialty Clinics
    Hospital
    Others
    Market segment by players, this report covers
    Pfizer Inc.
    Novartis AG
    Celgene Corporation
    Astellas Pharma Inc.
    Daiichi Sankyo Company, Limited
    Jazz Pharmaceuticals
    Boehringer Ingelheim International GmbH
    Johnson & Johnson
    Gilead Sciences, Inc.
    Amgen Inc.
    Takeda Pharmaceutical Company Limited
    Sunesis Pharmaceuticals, Inc.
    Agios Pharmaceuticals, Inc.
    Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Acute Myeloid Leukaemia Therapeutics product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Acute Myeloid Leukaemia Therapeutics, with revenue, gross margin and global market share of Acute Myeloid Leukaemia Therapeutics from 2018 to 2023.
    Chapter 3, the Acute Myeloid Leukaemia Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Acute Myeloid Leukaemia Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
    Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Acute Myeloid Leukaemia Therapeutics.
    Chapter 13, to describe Acute Myeloid Leukaemia Therapeutics research findings and conclusion.

    Buy now